Sanwezza
Sanwezza in Youtube Sanwezza in LinkedIn Sanwezza in Twitter Sanwezza in Facebook
News
A NEW ORIGINAL DRUG FOR THE TREATMENT OF JOINTS KARTILIUM BASED ON THE DEVIL'S CLAW ROOT INTRODUCED  IN UKRAINE
Jun 10 2015

A NEW ORIGINAL DRUG FOR THE TREATMENT OF JOINTS KARTILIUM BASED ON THE DEVIL'S CLAW ROOT INTRODUCED IN UKRAINE

Ukrainian pharmaceutical company Novalik-Pharm has launched a natural anti-inflammatory and analgetic Kartilium developed jointly with the company Sanwezza Lab GmbH.

A new drug Kartilium is effective in acute and chronic diseases of the joints: arthritis and osteoarthritis based on synovial cartilage damage with secondary changes of the articular surfaces. These diseases are the most common among all the pathologies of the locomotor system and a major cause of disability.

Kartilium has a unique composition of natural substances that can affect the process of inflammation and the condition of the articular cartilage. As part of this composition is standardized root extract of African plants Devil claws (Harpagophytum procumbens), manufactured by Naturex (France), as well as methylsulfonylmethane, manufactured by Eusa (France) - an organic compound which plays an important role in the repair of damaged tissues of the joints.

Due to anti-inflammatory and analgesic properties, root extract is widely used in traditional medicine of peoples in South Africa for gout and rheumatism treatment. In Europe and North America is used primarily to reduce the symptoms of arthritis.

Clinical response of Devil's claw root extract in inflammatory and degenerative diseases of the joints caused by the action of biologically active substances, the main one is Harpagoside. Specially developed technology allows obtaining the Harpagoside extract at a concentration not less than 20% and respectively advancing tenfold it single dose, as compared to other Devil's claw root extract. It has been proved that such dose of Harpagoside causes the therapeutic properties of the extract.

Experimental studies have confirmed the therapeutic effectiveness of a standardized extract, namely, reducing inflammation and pain, restore range of motion, improving the functionality and quality of life. Good Kartilium tolerance and lack of influence over gastrointestinal offer the challenge for a wide application for patients with acute and chronic diseases of the joints.

The company Pharmplanet is an official distributor of the drug. Kartilium is already available in national retail chain Pani Apteka and online store paniapteka.ua, and soon will come into pharmacy chains of Ukraine.